


Product Information



PD 166326

Item No. 9000988

CAS Registry No.: 185039-91-2
Formal Name: 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
MF: C₂₁H₁₆Cl₂N₄O₂
FW: 427.3
Purity: ≥95%
Stability: ≥1 year at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 212, 259, 307, 362 nm



Laboratory Procedures

For long term storage, we suggest that PD 166326 be stored as supplied at -20°C. It should be stable for at least one year.

PD 166326 is supplied as a crystalline solid. A stock solution may be made by dissolving the PD 166326 in the solvent of choice. PD 166326 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of PD 166326 in these solvents is approximately 25 mg/ml.

PD 166326 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PD 166326 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PD 166326 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

PD 166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC₅₀ = 8 nM) and Bcr/Abl-dependent cell growth (IC₅₀ = 0.4 nM).^{1,2} In addition to targeting a select group of receptor tyrosine kinases, PD 166326 also potently inhibits c-src (IC₅₀ = 6 nM).³ Orally administered PD 166326 is well tolerated and effectively blocks Bcr/Abl kinase activity *in vivo*.⁴ Moreover, PD 166326 affects a distinct set of kinases from those targeted by imatinib mesylate (STI571) and can reduce the growth of some imatinib-resistant cells both *in vitro* and *in vivo* in animal models of chronic myelogenous leukemia.²⁻⁴

References

1. Wisniewski, D., Lambek, C.L., Liu, C., *et al.* Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. *Cancer Res.* **62(15)**, 4244-4255 (2002).
2. Huron, D.R., Gorre, M.E., Kraker, A.J., *et al.* A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. *Clin. Cancer Res.* **9(4)**, 1267-1273 (2003).
3. Wolff, N.C., Veach, D.R., Tong, W.P., *et al.* PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. *Blood* **105(10)**, 3995-4003 (2005).
4. Azam, M., Nardi, V., Shakespeare, W.C., *et al.* Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. *Proc. Natl. Acad. Sci. USA* **103(24)**, 9244-9249 (2006).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/9000988

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery**.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy located on our website and in our catalog**.

Copyright Cayman Chemical Company, 11/26/2013

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com